These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19877967)

  • 1. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.
    Laucella SA; Mazliah DP; Bertocchi G; Alvarez MG; Cooley G; Viotti R; Albareda MC; Lococo B; Postan M; Armenti A; Tarleton RL
    Clin Infect Dis; 2009 Dec; 49(11):1675-84. PubMed ID: 19877967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances in the management of a long-neglected disease.
    Urbina JA
    Clin Infect Dis; 2009 Dec; 49(11):1685-7. PubMed ID: 19877968
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses.
    Alvarez MG; Bertocchi GL; Cooley G; Albareda MC; Viotti R; Perez-Mazliah DE; Lococo B; Castro Eiro M; Laucella SA; Tarleton RL
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004657. PubMed ID: 27128444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8low T cells expanded following acute Trypanosoma cruzi infection and benznidazole treatment are a relevant subset of IFN-γ producers.
    Marins-Dos-Santos A; Olivieri BP; Ferreira-Reis R; de Meis J; Silva AA; de Araújo-Jorge TC; Lannes-Vieira J; Cotta-de-Almeida V
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008969. PubMed ID: 33347472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.
    Perez-Mazliah DE; Alvarez MG; Cooley G; Lococo BE; Bertocchi G; Petti M; Albareda MC; Armenti AH; Tarleton RL; Laucella SA; Viotti R
    J Antimicrob Chemother; 2013 Feb; 68(2):424-37. PubMed ID: 23104493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease.
    Albareda MC; Laucella SA
    Mem Inst Oswaldo Cruz; 2015 May; 110(3):414-21. PubMed ID: 25993507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.
    Jones K; Versteeg L; Damania A; Keegan B; Kendricks A; Pollet J; Cruz-Chan JV; Gusovsky F; Hotez PJ; Bottazzi ME
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29311242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease.
    Argüello RJ; Albareda MC; Alvarez MG; Bertocchi G; Armenti AH; Vigliano C; Meckert PC; Tarleton RL; Laucella SA
    PLoS One; 2012; 7(5):e35966. PubMed ID: 22574131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological exhaustion and functional profile of CD8
    Pérez-Antón E; Egui A; Thomas MC; Simón M; Segovia M; López MC
    Acta Trop; 2020 Feb; 202():105242. PubMed ID: 31669531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
    Ferraz ML; Gazzinelli RT; Alves RO; Urbina JA; Romanha AJ
    Antimicrob Agents Chemother; 2009 Jan; 53(1):174-9. PubMed ID: 19001113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trypanosoma cruzi-Specific T-Cell Responses to Monitor Treatment Efficacy in Chronic Chagas Disease.
    Albareda MC; Natale MA; Cesar GL; Castro Eiro MD; Alvarez MG; Laucella SA
    Methods Mol Biol; 2019; 1955():339-348. PubMed ID: 30868539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benznidazole therapy in Trypanosoma cruzi-infected mice blocks thymic involution and apoptosis of CD4+CD8+ double-positive thymocytes.
    Olivieri BP; Farias-De-Oliveira DA; Araujo-Jorge TC; Cotta-de-Almeida V
    Antimicrob Agents Chemother; 2005 May; 49(5):1981-7. PubMed ID: 15855522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Treatment Outcomes of Antiparasitic Therapy in
    Albareda MC; Natale MA; De Rissio AM; Fernandez M; Serjan A; Alvarez MG; Cooley G; Shen H; Viotti R; Bua J; Castro Eiro MD; Nuñez M; Fichera LE; Lococo B; Scollo K; Tarleton RL; Laucella SA
    Front Immunol; 2018; 9():1958. PubMed ID: 30271399
    [No Abstract]   [Full Text] [Related]  

  • 19. A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.
    Egui A; Thomas MC; Fernández-Villegas A; Pérez-Antón E; Gómez I; Carrilero B; Del Pozo Á; Ceballos M; Andrés-León E; López-Ruz MÁ; Gainza E; Oquiñena E; Segovia M; López MC
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.
    Olivieri BP; Cotta-De-Almeida V; Araújo-Jorge T
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3790-6. PubMed ID: 12435678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.